Keith Berman, CEO of DECN commented, "GenViro for the Coronavirus (covid19) began as an outgrowth of our GenUltimate TBG product line. What makes the testing for the Coronavirus possible, and the GenUltimate TBG special, is the company's Impedance measurement technology.
https://www.frontiersin.org/articles/10.3389/fmicb.2015.00940/full
While infectious disease testing and management has not previously been a part of our business model, we seized on this "do good" opportunity because our "Gen" line of products are and have been manufactured since 2016 in what is ground zero for Coronavirus (covid19) in Daegu, Korea. The company will have available samples of the blood of those previously infected available for testing as the company quickly converts its GenUltimate TBG methods and Precise meter, into a precise infectious disease testing device for the screening for Coronavirus."
Review Recent Financial Reports »
Visit PharmaTech Solutions, Inc. »
GenViro! 12-Month Forecast
| Number of Months | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | SUM |
| Year 1 | Apr-20 | May-20 | Jun-20 | Jul-20 | Aug-20 | Sep-20 | Oct-20 | Nov-20 | Dec-20 | Jan-21 | Feb-21 | Mar-21 | |
| New Facility Customers | 0 | 0 | 0 | 0 | 0 | 5000 | 5000 | 5000 | 5000 | 5000 | 5000 | 5000 | |
| Retained Facilities | 0 | 0 | 0 | 0 | 0 | 0 | 5000 | 10000 | 15000 | 20000 | 25000 | 30000 | |
| Total Facility Customers | 0 | 0 | 0 | 0 | 0 | 5000 | 10000 | 15000 | 20000 | 25000 | 30000 | 35000 | 35,000 |
| Kits Consumed | 0 | 0 | 0 | 0 | 0 | 15,000,000 | 30,000,000 | 45,000,000 | 60,000,000 | 75,000,000 | 90,000,000 | 105,000,000 | 420,000,000 |
We are not resting our laurels with our GenViro development. Later product entries will be test methods for Polio, Ebola (Marburg), Bird Flu, and SARS. The cost of our test kits will be sold in a price range of $4.95 to $7.95 per use. The Coronavirus kit will be sold for $6.95. Each kit sold will carry enough diagnostic for two tests, a primary test, and a test in reserve in case of human error in administrating the primary test. We plan to provide our diagnostics initially for use at hospitals, doctors' offices, and clinics. Once production ramps up, we will offer testing kits and meters to patients for testing at-home.
Mr. Berman concluded, "As you might imagine with a product announcement of such importance, we have been contacted by a number of potential partners for our kit, as well as companies who were not chosen last time to proceed past the proposition stage. The company's first choice for partnering will be a company that made "the cut" last time for our GenUltimate! TBG product. We will discuss partnering potential in a coming release. For the moment, the company is content calling on big box and long term care chains through its existing distributors and agents."
DECN also markets its PetSure! test strip for the diabetic testing of dogs and cats, a diagnostic specifically designed to run on the market leding Zoetis Alpha Trak meter system as well as the GenUltimate! 4Pets Test strip and Avantage! meter. The company has also just introduced its GenExpidient! Universal Translator for bio-sensor devices of different manufacture. A GenExpidient! device will be included in every Covid19 kit. Having such a device will lower the incidence of cleaning and disinfecting the GenViro! meter.
ABOUT DECISION DIAGNOSTICS CORP
Decision
Forward-Looking Statements:
This release contains the company's forward-looking statements which are based on management's current expectations and assumptions as of March 11 2020, regarding the company's business and performance, its prospects, current factors, the economy, and other future conditions and forecasts of future events, circumstances, and results.
CONTACT INFORMATION:
Decision Diagnostics Corp.
Keith Berman (805) 446-2973
info@decisiondiagnostics.co
www.genultimate.com
www.genultimatetbg.com
www.petsureteststrips.com
www.pharmatechdirect.com
SOURCE: Decision Diagnostics Corp.
